These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 27929064)

  • 1. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
    Van Emburgh BO; Arena S; Siravegna G; Lazzari L; Crisafulli G; Corti G; Mussolin B; Baldi F; Buscarino M; Bartolini A; Valtorta E; Vidal J; Bellosillo B; Germano G; Pietrantonio F; Ponzetti A; Albanell J; Siena S; Sartore-Bianchi A; Di Nicolantonio F; Montagut C; Bardelli A
    Nat Commun; 2016 Dec; 7():13665. PubMed ID: 27929064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
    Arena S; Siravegna G; Mussolin B; Kearns JD; Wolf BB; Misale S; Lazzari L; Bertotti A; Trusolino L; Adjei AA; Montagut C; Di Nicolantonio F; Nering R; Bardelli A
    Sci Transl Med; 2016 Feb; 8(324):324ra14. PubMed ID: 26843189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
    Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
    Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
    Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
    Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic landscape of response to EGFR blockade in colorectal cancer.
    Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
    Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 10. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.
    Dempke WC; Heinemann V
    Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
    Hobor S; Van Emburgh BO; Crowley E; Misale S; Di Nicolantonio F; Bardelli A
    Clin Cancer Res; 2014 Dec; 20(24):6429-38. PubMed ID: 24916700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
    Arena S; Bellosillo B; Siravegna G; Martínez A; Cañadas I; Lazzari L; Ferruz N; Russo M; Misale S; González I; Iglesias M; Gavilan E; Corti G; Hobor S; Crisafulli G; Salido M; Sánchez J; Dalmases A; Bellmunt J; De Fabritiis G; Rovira A; Di Nicolantonio F; Albanell J; Bardelli A; Montagut C
    Clin Cancer Res; 2015 May; 21(9):2157-66. PubMed ID: 25623215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
    Bonin S; Donada M; Bussolati G; Nardon E; Annaratone L; Pichler M; Chiaravalli AM; Capella C; Hoefler G; Stanta G
    Tumour Biol; 2016 Jun; 37(6):7295-303. PubMed ID: 26666825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
    Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A
    Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
    Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
    Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
    Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
    Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.